{"id":"e3252b96-4b15-55b9-b4e4-085e8459b315","stable_key":"4d8e4781-3878-5818-8d0a-7dbd6e024555:chromium-diabetes-fasting-glucose-positive","predicate":"reduces","statement":"The 1,000 µg/day group had lower fasting glucose than placebo at two and four months; four-month values were 7.1 versus 8.8 mmol/L.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"89ee5355-685c-5f89-b43d-aa89fa290295","mechanism_event_label":"Fasting glucose was also lower in the higher-dose group.","subject":{"id":"89d5d39c-2663-5e0c-8eae-562a5b25a47d","slug":"chromium-iii-picolinate","display_name":"Chromium(III) picolinate / CrPic","entity_type_key":"chemical_species"},"object":{"id":"c14f8db4-0b3a-5323-b90b-21983e884a97","slug":"fasting-plasma-glucose","display_name":"Fasting plasma glucose","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"89ee5355-685c-5f89-b43d-aa89fa290295","stable_key":"4d8e4781-3878-5818-8d0a-7dbd6e024555:chromium-diabetes-fasting-glucose-positive-event","event_type":"observed_intervention","label":"Fasting glucose was also lower in the higher-dose group.","description":"The 1,000 µg/day group had lower fasting glucose than placebo at two and four months; four-month values were 7.1 versus 8.8 mmol/L.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"89d5d39c-2663-5e0c-8eae-562a5b25a47d","slug":"chromium-iii-picolinate","display_name":"Chromium(III) picolinate / CrPic","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"c14f8db4-0b3a-5323-b90b-21983e884a97","slug":"fasting-plasma-glucose","display_name":"Fasting plasma glucose","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/chromium-research/9356027.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69\", \"start_char\": 0, \"end_char\": 1941, \"text_sha256\": \"9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized three-arm supplementation trial; 180 adults","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Chromium research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"chromium","display_name":"Chromium","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human with treated type 2 diabetes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Fasting glucose was also lower in the higher-dose group.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"HbA1c, glucose, insulin and lipids","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"fa102ddb-c114-5e10-a172-21c3a3f5596c","evidence_kind":"source_excerpt","locator":"Lines 1030-1041","start_line":1030,"end_line":1041,"excerpt":"### chromium-diabetes-fasting-glucose-positive\nThe 1,000 µg/day group had lower fasting glucose than placebo at two and four months; four-month values were 7.1 versus 8.8 mmol/L.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Fasting glucose was also lower in the higher-dose group.\norganism: Human with treated type 2 diabetes\ntissue_or_cell_type: HbA1c, glucose, insulin and lipids\nexperimental_model: Randomized three-arm supplementation trial; 180 adults\nlimitations: Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.\nexposure: Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/9356027.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69\", \"start_char\": 0, \"end_char\": 1941, \"text_sha256\": \"9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69\"}\n[chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786","model_system":"Randomized three-arm supplementation trial; 180 adults","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"fa96342a-ca01-5425-98d9-d50e29bf0abd","stable_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"6cae22f9104c6de041b25c23b0fd2884cc57707ac0c9a87c20b0e665d16de5ab","revision_id":"22893798-8329-5295-9c9d-82169032fc79","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}